101 results on '"Buzdar, A. U."'
Search Results
2. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma.
3. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy.
4. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy.
5. The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.
6. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma.
7. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference.
8. Cranial nerve palsies in metastatic breast cancer due to osseous metastasis without intracranial involvement.
9. Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen.
10. Peptichemio versus melphalan (L-PAM) in advanced breast cancer.
11. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen.
12. Combination chemotherapy for breast cancer metastatic to bone marrow.
13. Tamoxifen-induced hypercalcemia in breast cancer.
14. Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens.
15. Management of inflammatory carcinoma of breast with combined modality approach - an update.
16. Estrogen receptor: a prognostic factor in breast cancer.
17. Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy.
18. Causes of death in breast cancer: a clinicopathologic study.
19. Pulmonary toxicity of mitomycin.
20. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG.
21. Combined chemoimmunotherapy for advanced breast cancer: a comparison of BCG and levamisole.
22. Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer.
23. The order of administration of chemotherapy and radiation and its effect on the local control of operable breast cancer.
24. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy.
25. A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma.
26. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients.
27. Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer?
28. Sequential cyclic combined hormonal therapy for metastatic breast cancer.
29. The role of serum CEA as a prognostic indicator in stage II and III breast cancer patients treated with adjuvant chemotherapy.
30. Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer.
31. Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs.
32. Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer. A prospective, randomized trial.
33. Chemotherapy with mitoxantrone in combination with continuous infusion vinblastine for metastatic breast cancer.
34. Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy.
35. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy.
36. Management of locoregional recurrent breast cancer.
37. Trioxifene mesylate in the treatment of advanced breast cancer.
38. Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy.
39. A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer.
40. Early and delayed clinical cardiotoxicity of doxorubicin.
41. A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma.
42. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy.
43. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
44. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio.
45. Tumor-associated fever in breast cancer.
46. Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial.
47. Benign versus malignant hepatic lesions. A diagnostic dilemma with breast cancer patients.
48. The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy.
49. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support.
50. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.